Peer Exchange

This AJMC Peer Exchange program brings together multiple myeloma experts to discuss the rapidly evolving role of bispecific antibodies across treatment settings. Panelists examine emerging clinical data, real world evidence, safety considerations, and practical strategies for integrating these therapies alongside CAR T-cell therapy and antibody drug conjugates. The discussion also highlights ongoing studies evaluating the potential use of bispecifics earlier in the treatment landscape, as well as opportunities to improve access, optimize sequencing, and support effective transitions between academic and community care.

Panelists discuss how advanced practice providers are driving transformation in Alzheimer disease management through early detection, personalized treatment, and comprehensive patient and caregiver support. Across 17 videos, they highlight the growing leadership of advanced practice providers (APPs) in multidisciplinary collaboration, operational efficiency, and equitable access to care.

**One-Sentence Summary:** Panelists discuss how APPs are redefining Alzheimer care through leadership, coordination, and holistic patient engagement.

Panelists discuss how integrating metabolic, pharmacologic, and multidisciplinary strategies can bridge the obesity–MASH divide to improve early detection, treatment outcomes, and long-term public health impact.

This AJMC Peer Exchange® program, moderated by Ryan Haumschild, PharmD, MS, MBA, brings together clinical pharmacy specialists Shahrier Hossain, PharmD; Michael Singel, PharmD; and hematologist Naresh Bumma, MD, to explore how emerging therapies are reshaping care for relapsed/refractory multiple myeloma (RRMM). The panel reviews disease biology, conventional first-line and later-line options, and then dives into bispecific antibodies—including linvoseltamab, teclistamab, talquetamab, and elranatamab—covering mechanisms of action, pivotal approval data, dosing schedules, and toxicity management. They close by comparing operational considerations across bispecifics and CAR T therapies, emphasizing practical dosing, CRS/ICANS management, and the biggest unmet needs and future advances expected over the next 5 years.

Panelists discuss how policy, payer practices, and clinical evidence intersect to shape oncology access, innovation, and affordability. They explore how aligning coverage frameworks with evolving evidence, real-world data, and patient-centered values can improve outcomes and sustain innovation in a rapidly changing health care landscape.

Panel of experts will explore opportunities for diagnosing and treating desmoid tumors.

Panelists discuss how evolving schizophrenia care requires balancing early diagnosis, effective and safe treatment options, and equitable access to novel therapies to improve patient outcomes and quality of life.

Panel of experts will explore treatment of EGFR + NSCLC. Panelists discuss efficacy and safety data from recent studies and how these data are shaping EGFR+ NSCLC management in clinical practice. Panelists also talk about increasing interest in the use of subcutaneous formulations of NSCLC treatments and how this mode of administration can advance patient care in EGFR+ NSCLC.

Panelists discuss how evolving clinical evidence, real-world outcomes, and patient-reported data inform the selection, sequencing, and implementation of third-line therapies for metastatic colorectal cancer, highlighting the importance of individualized care, cross-setting collaboration, and strategies to enhance community adoption and patient quality of life.

Experts discuss the clinical benefits of topical therapies in managing pediatric atopic dermatitis (AD), strategies to delay biologic treatments, and how health economics and outcomes research (HEOR) informs cost-effective treatment choices and healthcare resource optimization.

Panelists discuss how acute myeloid leukemia treatment has evolved from a one-size-fits-all approach to personalized medicine incorporating genetic profiling, targeted therapies like venetoclax and IDH inhibitors, emerging oral regimens, and comprehensive patient assessments that consider not only traditional fitness criteria but also social determinants of health, quality of life factors, and the potential for curative versus palliative care in different patient populations.

Panelists discuss how heart failure management has evolved from limited treatment options to a comprehensive approach requiring multidisciplinary collaboration, early intervention strategies, and integration of multiple evidence-based therapies including SGLT2 inhibitors, ARNIs, and mineralocorticoid receptor antagonists to address the substantial clinical and economic burden of this condition affecting millions of Americans.

Ryan Haumschild, PharmD, MS, MBA, CPEL; Andrew Alexis, MD, MPH; April W. Armstrong, MD, MPH; Andrew M. Mastro, MS, PA-C; and Mark Makhinson, PharmD, discuss how atopic dermatitis is an immune-mediated disease with heterogeneous pathways that present differently across skin tones, requiring health care professionals to recognize diverse clinical manifestations, address educational gaps in understanding the complex immunopathogenesis, and ensure equitable access to targeted biologic therapies through improved training, clinical trial representation, and coordinated care teams.

Experts discuss the unmet clinical and economic needs in arrhythmia evaluation—particularly in patients with comorbidities—highlighting how early detection and predictive solutions can improve care and reduce costs, while integrated workflows support better outcomes and align with broader population health goals.

Panelists discuss the evolving disease burden and health equity challenges of hidradenitis suppurativa, recent therapeutic advancements, and the comprehensive economic impact, highlighting opportunities for improved clinical outcomes and cost-effective, equitable care.

Panelists describe the aggressive clinical and molecular features of KMT2A-rearranged acute myeloid leukemia (AML)—including its menin-dependent biology and poor response to standard chemotherapy—while evaluating current and emerging therapies like Menin inhibitors, and highlighting persistent challenges in early diagnosis, equitable access, and delivering specialized care across health care settings.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Ryan Haumschild, PharmD, MBA, MS; Faith Davies, MD; Shachar Peles, MD, and Sagar Lonial MD, FACP discuss how quadruple therapy regimens incorporating CD38 antibodies have become the standard of care for both transplant-eligible and transplant-ineligible multiple myeloma patients, with treatment decisions guided by patient risk stratification, minimal residual disease monitoring, and the balance between achieving deep responses and maintaining quality of life.

A panel of experts describes the impact of subcutaneous formulations on oncology workflows and discusses actionable strategies for oncology practice transformation to successfully integrate subcutaneous therapies into clinical workflows.

Nihar Desai, MD, MPH; Kenny J. Cole, MD, MS; Jacinda Mawson Nicklas, MD, MPH, MA; Esra Karslioglu French, MD, MBA, and Goutham Rao, MD, discuss how recent advances in GLP-1 receptor agonists and other therapies are transforming the treatment of type 2 diabetes and obesity by enabling a paradigm shift from reactive glucose management to proactive weight-focused care that addresses the root causes of cardiometabolic disease, while emphasizing the critical need for multidisciplinary teams, bias-free patient communication, and systematic healthcare delivery changes to overcome barriers like provider time constraints, medication access, and weight stigma.

Panelists discuss how the clinical and economic burden of idiopathic and progressive pulmonary fibrosis (IPF and PPF) underscores the need for earlier diagnosis, improved care coordination, and emerging therapies that may close treatment gaps while balancing efficacy with health care resource utilization.

Julie A. Parsons, MD; John Brandsema, MD; and Tina Duong, MPT, PhD, discuss how management approaches for older patients with spinal muscular atrophy (SMA) differ from those for infants, highlighting the importance of individualized treatment goals focused on independence, fatigue management, quality of life, and the challenges of measuring outcomes with currently available assessment tools, while also exploring current and emerging therapies, including splice modifiers and potential intrathecal gene therapy options.

Experts cover key updates in the management of patients with Neurofibromatosis Type 1 with Plexiform Neurofibromas, or NF1-PN, while also exploring the pathophysiology of NF1-PN, the management of it and potential treatment options

Ryan Haumschild, PharmD, MS, MBA, CPEL; Elizabeth Castronovo, NP; Martin Dietrich, MD, PhD; Mary Grizzard, MSN, FNP; and Christine M. Lovly, MD, PhD, FASCO, discuss how advances in ALK-positive non–small cell lung cancer (ALK+ NSCLC) treatment, including 5-year CROWN trial data for lorlatinib, recent ensartinib approval, comparative efficacy against brain metastases, toxicity management strategies, and sequencing approaches following progression are reshaping clinical decision-making to optimize long-term patient outcomes.

Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC), assess the evolving role of pharmacists in treatment optimization and patient education, and analyze access challenges to mCRC therapies, proposing strategies to improve patient access.

Nihar Desai, MD, MPH, leads a panel of experts in a discussion surrounding lipoprotein(a) (Lp[a]) as a causal risk factor for atherosclerotic cardiovascular disease and aortic stenosis, exploring the clinical utility and guidelines for Lp(a) measurement, and addressing barriers and strategies for optimizing the management of Lp(a)-associated risk.

Panelists discuss how the latest data from the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024) on bispecific therapies for B-cell lymphomas, including epcoritamab, mosunetuzumab, and odronextamab, influence treatment strategies, address toxicity management, and highlight the challenges and opportunities in expanding access to these therapies across academic and community settings.